EUVIMEDEUVIMED entdecken
Crossref

Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1697b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Hyperphosphatemia, Renal Insufficiency, Chronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved the sodium/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah – Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective or as monotherapy when phosphate binders cannot be tolerated. Tenapanor is the first NHE3 inhibitor to be approved in the US for hyperphosphatemia. It was previously approved as Ibsrela to treat irritable bowel syndrome with constipation (IBS-C).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaRenal Insufficiency, ChronicHumansIsoquinolinesSulfonamidesFerric CompoundsPhosphatesRenal Dialysis

Stichwörter der Autor:innen

AuryxiaCalphronFosrenolIbsrelaRenvelaVelphoroXphozahadverse effectscalcium acetatechronic kidney diseasedosagedrug interactionsefficacyferric citrateirritable bowel syndrome

Substanzen

tenapanorIsoquinolinesSulfonamidesFerric CompoundsPhosphates

Zitieren

APA

(2024). Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1697b

Vancouver

Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1697b

BibTeX
@article{euvimed2024,
  title = {Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1697b}
}
Kostenlos starten →